Sponsor content
269 result(s) found, displaying 21 to 30
-
Australian public assessment report (AusPar)Opsynvi (macitentan/tadalafil) is approved for maintenance treatment of pulmonary arterial hypertension in adult patients.
-
Prescription medicine registrationActive ingredients: amivantamab.
-
Prescription medicine registrationActive ingredients: lazertinib mesilate monohydrate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SETRELVO ustekinumab 90 mg/ 1 mL solution for injection pre-filled pen (One-Press patient-controlled injector).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SETRELVO ustekinumab 45 mg/ 0.5 mL solution for injection pre-filled pen (One-Press patient-controlled injector).
-
Cancellation by sponsorRequested by Janssen-Cilag Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TALVEY talquetamab 40 mg/mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TALVEY talquetamab 2 mg/mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OPSYNVI 10/40 macitentan 10 mg / tadalafil 40 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SETRELVO ustekinumab 45 mg/0.5 mL solution for injection vial.